Front Psychol. 2025 Aug 19;16:1607317. doi: 10.3389/fpsyg.2025.1607317. eCollection 2025. ABSTRACT INTRODUCTION: Several studies have demonstrated a reduced… Read More
admin
EFORT Open Rev. 2025 Sep 4;10(9):646-659. doi: 10.1530/EOR-2025-0071. ABSTRACT PURPOSE: This study aimed to comprehensively review the… Read More
Int J Endocrinol. 2025 Aug 26;2025:2357272. doi: 10.1155/ije/2357272. eCollection 2025. ABSTRACT Aims: Dipeptidyl peptidase-4 (DPP4) inhibitors are… Read More
Clin Rheumatol. 2025 Sep 4. doi: 10.1007/s10067-025-07671-x. Online ahead of print. ABSTRACT OBJECTIVES: Pulmonary hemorrhage (PH) represents… Read More
Zhonghua Nei Ke Za Zhi. 2025 Sep 1;64(9):831-837. doi: 10.3760/cma.j.cn112138-20250508-00262. ABSTRACT Objective: To analyze the clinical characteristics… Read More
Zhonghua Nei Ke Za Zhi. 2025 Sep 1;64(9):891-899. doi: 10.3760/cma.j.cn112138-20240927-00610. ABSTRACT 系统性红斑狼疮（SLE）的发病机制复杂，目前治疗选择相对有限。Ⅰ型干扰素通路作为同时调控固有与适应性免疫的核心致病机制，已成为药物研发关键靶点。靶向Ⅰ型干扰素受体的anifrolumab 是近十年首个获批治疗中重度SLE的创新生物制剂。围绕Ⅰ型干扰素的产生和受体激活通路的多种靶向治疗药物正处于不同研发阶段。各靶向药物在临床应用中表现出不同的疗效和特点，差异可能源于作用机制特异性及患者异质性。本综述系统阐述Ⅰ型干扰素通路致病机制与靶向治疗策略的前沿进展，旨在为临床精准用药提供理论依据。. PMID:40904301 | DOI:10.3760/cma.j.cn112138-20240927-00610 Read More
Clin Cosmet Investig Dermatol. 2025 Aug 29;18:2047-2066. doi: 10.2147/CCID.S533281. eCollection 2025. ABSTRACT OBJECTIVE: The aim of this… Read More
Arterioscler Thromb Vasc Biol. 2025 Sep 4. doi: 10.1161/ATVBAHA.125.322574. Online ahead of print. ABSTRACT BACKGROUND: The underlying… Read More
The incidence of kidney stones is higher among patients with rheumatoid arthritis vs. those without RA, according… Read More
Nat Methods. 2025 Sep 3. doi: 10.1038/s41592-025-02793-1. Online ahead of print. ABSTRACT T cells recognize antigens and… Read More